IRCT20210612051548N1
Not yet recruiting
Phase 2
Targeted a-Therapy in Metastatic Castration Resistant Prostate Cancer with 225Ac-PSMA-617
Boushehr University of Medical Sciences0 sites10 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Prostate cancer.
- Sponsor
- Boushehr University of Medical Sciences
- Enrollment
- 10
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients must have had progressive metastatic castration\-resistant prostate cancer.
- •Patients must have a positive 68Ga\-PSMA\-11 PET/CT scan.
- •Patients must have recovered or stabilized to \= Grade 2 from all clinically significant toxicities related to prior prostate cancer therapy.
- •Patients must have an ECOG performance status of 0 to 2\.
Exclusion Criteria
- •Previous treatment with Strontium\-89, Samarium\-153, Rhenium\-186, Rhenium\-188, Radium\-223 or hemi\-body irradiation or previous PSMA\-targeted radioligand therapy.
- •The patient was diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment (Patients with a prior history of malignancy who have been disease\-free for more than 3 years are eligible).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Treatment of patients with castration-resistant metastatic prostate cancer with nuclear medicine procedureCastration resistant metastatic prostate cancer.Malignant neoplasm of prostateIRCT20180113038331N1Mashhad University of Medical Sciences20
Active, not recruiting
Phase 1
To investigate safety and effectiveness of PSMA directed [177-Lu]-PNT2002, an investigational agent for treatment of patients with mCRPCEUCTR2021-002641-15-SEPoint BioPharma Inc.390
Recruiting
Phase 3
SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu- PNT2002 PSMA Therapy After Second-line Hormonal Treatmentprostate cancer10027655NL-OMON54469POINT BioPharma,30
Active, not recruiting
Phase 1
To investigate safety and effectiveness of PSMA directed [177-Lu]-PNT2002, an investigational agent for treatment of patients with mCRPCMetastatic Castrate Resistant Prostate Cancer (mCRPC)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-002641-15-NLPoint BioPharma Inc.390
Active, not recruiting
Not Applicable
Metastasis-directed Therapy in Castration-refractory Prostate CancerCastration-resistant Prostate CancerNCT04222634Universitaire Ziekenhuizen KU Leuven18